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A role for cardiopulmonary exercise testing 
in detecting physiological changes underlying 
health status in Idiopathic pulmonary fibrosis: 
a feasibility study
R. Davis1, C. Dixon2, A. B. Millar1,2, N. A. Maskell2 and S. L. Barratt1,2* 
Abstract 
Introduction: There is limited data available on the use of CPET as a predictive tool for disease outcomes in the set-
ting of IPF. We investigated the feasibility of undertaking CPET and the relationship between CPET and quality of life 
measurements in a well-defined population of mild and moderate IPF patients.
Methods: A prospective, single-centre observational study.
Results: Thirty-two IPF patients (mild n = 23, moderate n = 9) participated in the study, n = 13 mild patients attended 
for repeat CPET testing at 12 months. At baseline, total K-BILD scores and total IPF-PROM scores significantly cor-
related with 6MWT distance, but not with baseline FVC % predicted, TLco % predicted, baseline or minimum  SpO2. 
 VO2 peak/kg at AT positively correlated with total scores, breathlessness/activity and chest domains of the K-BILD 
questionnaire (p < 0.05).  VO2 peak significantly correlated with total IPF PROM scores and wellbeing domains (p < 0.05), 
with a trend towards statistical significance for total IPF-PROM and  VO2 peak/kg at anaerobic threshold (p = 0.06).
There was a statistically significant reduction in FVC% predicted at 12 months follow up, although the mean absolute 
decline was < 10% (p < 0.05). During this period  VO2 peak significantly reduced (21.6 ml/kg/min ± 2.9 vs 19.1 ± 2.8; 
p = 0.017), with corresponding reductions in total K-BILD and breathlessness/activity domains that exceeded the 
MCID for responsiveness. Lower baseline  VO2 peak/kg at anaerobic threshold correlated with greater declines in total 
K-BILD scores (r =  − 0.62, 0.024) at 12 months. Whilst baseline FVC% predicted or TLco % predicted did not predict 
change in health status,
Conclusion: We have shown that it is feasible to undertake CPET in patients with mild to moderate IPF.
CPET measures of  VO2 peak correlated with both baseline and change in K-BILD measurements at 1 year, despite rela-
tively stable standard lung function (declines of < 10% in FVC), suggesting its potential sensitivity to detect physiologi-
cal changes underlying health status.
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Introduction
Idiopathic Pulmonary Fibrosis (IPF) is a progressive 
fibrosing lung disease of increasing prevalence [1], asso-
ciated with median survival of only 3–5 years from diag-
nosis [2, 3]. Disease heterogeneity continues to present 
challenges for clinicians with regards to prognostication 
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and optimal timings for lung transplantation and/or 
advanced care planning [4, 5]. In the setting of large-scale 
clinical trials, a decline in forced vital capacity (FVC) has 
been used as a primary outcome measure [6, 7] and as a 
surrogate for mortality, although this has not been uni-
versally endorsed [8, 9].
Cardiopulmonary exercise testing (CPET) is the con-
sidered the gold standard for evaluating maximal/
symptom-limited exercise tolerance, encompassing 
respiratory, cardiovascular and musculoskeletal assess-
ments, in a controlled laboratory environment [10–12].
However there is limited data available on the use of 
CPET as a predictive tool for disease outcomes in the set-
ting of IPF. A recent systematic review identified only two 
small-scale prospective studies that investigated the role 
of CPET in the prognostication in IPF [13, 14] and con-
cluded that there was insufficient evidence to support its 
use in facilitating ‘real world’ clinical decisions at the cur-
rent time.
We have investigated the feasibility of undertaking 
CPET in a population of mild and moderate IPF patients 
in terms of the attrition of participants, information on 
safety data, and willingness to engage with the study 
protocol. Secondary end-points included: the change in 
CPET parameters over a 1  year period and the correla-
tion between baseline CPET parameters and change in 
lung function, 6MWT and health status at 1 year.
We hypothesised that CPET would be feasible in popu-
lation of mild to moderate IPF patients and more sensi-




This was a prospective, single-centre observational study 
undertaken at a large secondary care institution in the 
UK, providing secondary and tertiary care to patients 
with Interstitial Lung disease (ILD) within the South-
West of England. The study was approved by the Health 
Research Authority and Research Ethics Committees 
(IRAS 223450).
Study subjects
Patients with a multidisciplinary team (MDT) diagnosis 
of IPF, based upon the American Thoracic Society/Euro-
pean Respiratory Society 2018 guidelines [15], were pro-
spectively recruited to the study between June 2018 and 
May 2019. Written informed consent was obtained from 
each patient.
Patients were divided into a ‘mild’ or ‘moderate’ cate-
gory dependent on their baseline Forced Vital Capacity 
(FVC ≥ 50% −  < 80%: moderate; FVC ≥ 80% mild). Those 
patients in the ‘mild’ disease group would undertake both 
a baseline and repeat CPET at 12 months. It was decided 
by the study committee, due to the uncertainty of the 
ability of those with reduced lung function to perform a 
maximal exercise test, that those in the ‘moderate’ dis-
ease group would undertake only a baseline CPET test.
Inclusion and exclusion criteria
Inclusion criteria were an MDT consensus diagnosis of 
IPF, male or female aged ≥ 40 years, TLCO ≥ 50% pre-
dicted and FVC ≥ 50% with written informed consent for 
study participation.
Key exclusion criteria were: FEV1/FVC ratio < the 
lower limit of normal, mobility issues preventing the par-
ticipant to undertake cycle ergometry, history of myocar-
dial infarction (MI) within 6 months or unstable angina 
within 1 month, uncontrolled arrhythmias causing symp-
toms or haemodynamic compromise, history of recent 
syncope (within last 6 months), acute thrombosis within 
previous 6  months, cognitive impairment/ inability to 
perform CPET, severe or untreated arterial hypertension 
(> 200 mmHg systolic at rest, > 120 mmHg diastolic) and 
patients using oxygen treatment.
Participant testing
Pulmonary function testing
Pulmonary function tests were performed in accord-
ance with ATS/ERS guidelines [16], using the European 
Community of Coal and Steel (ECCS)  reference  equa-
tions  [17]. Forced expiratory volume during first sec-
ond of expiration  (FEV1), forced vital capacity (FVC), 
and transfer factor for carbon monoxide (TLCO) were 
undertaken at baseline (within 4  weeks of CPET) and 
at 12 months (± 4 weeks) (nSpire HDpft, nSpire Health 
GmbH, Germany). The MRC score, age (years), height 
(meters), and body weight of the patients (kilograms) 
were also recorded.
6 minute walking test (6MWT)
A 6MWT was performed at baseline (and within 
3  months of CPET) according to ATS guidelines [18], 
using the Enright reference equation [19]. The follow-
ing data were collected and analysed: distance achieved 
(metres), oxygen saturation at the initiation of the test, 
the minimum saturation level, percentage of theoretical 
distance achieved and at the end of the test.
Cardiopulmonary exercise testing (CPET)
CPET was performed using a standardized protocol 
in accordance with the American Thoracic Society/
American College of Chest Physicians (ATS/ACCP) 
statement [20], using Wasserman [21] and Jones [22] 
reference equations. All patients underwent a symp-
tom-limited CPET to exhaustion or intolerability with 
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an electromagnetically braked cycle ergometer (Ergose-
lect 100, ergoline GmbH, Germany) using a ramp 
protocol over 8–12  min. The protocol included 3  min 
of rest, 2  min of unloaded cycling (at 60 revolutions 
per min), followed by a progressively increasing work 
rate in a ramp fashion, and a recovery period (patient 
dependent). The work rate increment for each ramped 
exercise test was selected depending on the patient’s 
level of daily activity (either 5 or 10 W/min ramp).
Subjects were asked to maintain a rate of 60 revolu-
tions per minute throughout the exercise period. Sev-
eral markers were used to determine if a maximal effort 
test was performed; a respiratory exchange ratio (RER; 
 VCO2/VO2) ≥ 1.1, maximum heart rate (HR max) > 90% 
of maximum predicted HR (220-age), maximum min-
ute ventilation during exercise > 85% predicted based 
on MVV at rest (maximum voluntary ventilation) and 
a plateau in  VO2 with an increased workload. CPET 
could be discontinued at the discretion of the supervis-
ing attendant if clinically indicated.
Cardiopulmonary data were collected and analysed 
with nSpire Zan 600 USB system (nSpire Health GmbH, 
Germany).
The following parameters were recorded:
• Peak oxygen consumption  (VO2 peak, ml/kg/min),
• Oxygen consumption at anaerobic threshold
• Carbon dioxide production  (VCO2)
• Peak minute ventilation (VE peak)(marker of venti-
latory function during exercise),
• VE/VCO2 slope as derived from the above values 
(reflects changes in ventilatory drive)
• Peripheral capillary oxygen saturation  SpO2 
(marker of hypoxaemia indicating possible ventila-
tory limitation to exercise)
• Peak power output (W)(marker of musculoskeletal 
function)
• Heart rate (HR) (marker of cardiac function during 
exercise),
• Breathing reserve (BR)
Anaerobic threshold was determined noninva-
sively through the plot of  VCO2 versus  VO2 (V-slope 
method). Predicted minute ventilation was automati-
cally calculated by the software as a function of maxi-
mal voluntary ventilation (MVV), where MVV = FEV1 
L × 40. The BR was automatically calculated from the 
software as the difference between the maximum vol-
untary ventilation at rest and the peak ventilation. The 
% predicted  VO2 peak and % theoretical  VO2 peak at 
AT were not determined in this study as it was felt that 
populations deriving existing reference equations and 
normal standards were not representative of the male 
predominant and elderly population, characteristic of 
IPF patients/populations.
Health status questionnaires and patient‑reported 
outcomes
Patients were asked to complete the King’s Brief ILD 
questionnaire (K-BILD) [23] and IPF-Patient reported 
outcome measure (IPF-PROM) [24], in addition to the 
Leicester Cough visual analogue scale (VAS) for cough 
[25] and Bristol VAS for breathlessness and fatigue [26], 
at baseline and at 12 months.
The K-BILD is a self-completed health status ques-
tionnaire that comprises 15 items in three domains of 
psychological, breathlessness and activities and chest 
symptoms. The K-BILD scoring system implements logit 
transformation of raw item response scores to provide 
total score ranges of 0–100, where 100 represents best 
health status. The minimally important clinical difference 
(MCID) for the logit version of the K-BILD questionnaire 
is 5 for total K-BILD, 6 for Psychological, 7 for Breath-
lessness and activities and 11 for Chest symptoms [27].
The IPF-PROM [24] is a self-completed 12 item health 
status questionnaire that measures the physical and psy-
chological experience of breathlessness; emotional well-
being and fatigue. The questionnaire has been validated 
in terms of face and content validity. The scores range 
from 12 to 48, where 48 indicates worst health status.
Outcomes
We wished to study the feasibility of undertaking CPET 
in a population of mild and moderate IPF patients: the 
attrition of participants, information on safety data, and 
willingness to engage with the study protocol. Second-
ary end-points included: the change in CPET parameters 
over a 1 year period and the correlation between baseline 
CPET parameters and change in lung function, 6MWT 
and health status at 1 year.
Statistical analysis
Categorical variables are reported as absolute numbers 
and percentages. Normality of continuous data was ini-
tially verified using D’Agostino and Pearson normal-
ity test. Mean and standard deviations (SD) were used 
to describe parametric data; median and interquartile 
range (IQR, in brackets) for non-parametric data. Dif-
ferences among two groups were verified by t-test with 
Welch’s correction for continuous parametric data or 
Mann–Whitney U for non-parametric data. Fisher’s 
exact test was used to compare two categorical vari-
ables (with small sample size), whilst χ2-test was used to 
compare multiple categorical variables or larger sample 
sizes. Paired t-tests were used for comparison of para-
metric variables from baseline to 12 months or Wilcoxon 
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in the case of non-parametric data. Pearson’s correlation 
was used to determine correlations between parametric 
variables. Data were analysed using GraphPad Prism ver-




Forty-two consecutive IPF patients were prospectively 
enrolled to the study. Four patients subsequently with-
drew consent, 1 patient died and 5 patients developed 
exclusion criteria prior to commencement of the study. A 
further 5 patients did not complete the study and were 
lost to follow up (4 mild, 1 moderate). The final popula-
tion studied thus consisted of 27 patients (mild n = 19 
and moderate n = 8) (Fig.  1). Patients were predomi-
nantly male (n = 22, 82%) with a mean age of 75  years 
(± 6.0  years) and were symptomatic at baseline with 
a median MRC breathlessness score of 2 (IQR 2–3). 
Approximately one third (33%, n = 9) of patients (mild 
n = 5, moderate n = 4) received antifibrotics during the 
observational period. At completion of 1 year follow up, 
all patients remained alive.
Feasibility
There was excellent willingness to engage with the study 
protocol.
All patients achieved a RER > 1.1 and the vast major-
ity of patients also achieved > 80% of their maximal 
predicted heart rate (25/27, 93%) and /or had limited 
breathing reserve, providing corroboration that patients 
performed at maximal effort.
At baseline, all participants achieved the anaerobic 
threshold during testing and at 1 year follow up only one 
patient failed to achieve the anaerobic threshold.
Breathlessness and fatigue were the most commonly 
cited reasons for terminating CPET. Of patients complet-
ing the study (n = 27; 19 mild and 9 moderate IPF), base-
line CPET was terminated due to breathlessness in 37% 
(10/27), the majority of which had mild IPF (90%, 9/10). 
Leg/muscle fatigue was cited as a reason for terminating 
CPET in 63% patients (17/27), of which 59% (10/17) had 
mild disease. There were no significant differences in the 
reasons for terminating CPET between those that com-
pleted and did not complete follow-up.
At 1  year repeat CPET, 54% (7/13) described breath-
lessness as the reason for stopping and 38% (5/13) muscle 
Fig. 1 Consort diagram of study participants.  TLco, transfer factor; FEV1/FVC < LLN, Forced expiratory volume in 1 s/Forced vital capacity < lower 
limit of normal; IPF idiopathic pulmonary fibrosis; 6MWT six minute walk test; CPET cardiopulmonary exercise testing
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fatigue. A dry mouth was cited as the main contributing 
reason for stopping in one patient.
One patient described dizziness related to his breath-
lessness during CPET but no other adverse events were 
recorded. There were no serious adverse events.
Baseline measurements between mild and moderate IPF 
groups
Baseline demographics between mild and moderate IPF 
groups were statistically comparable (Table  1). As per a 
priori subgroup definitions, participants in the mod-
erate IPF group had a statistically lower baseline FVC 
% predicted compared to those in the mild IPF group 
(mild 99% predicted ± 10.0, range 85–125% predicted) vs 
moderate 70% predicted ± 5.1, range 62–75% predicted, 
p < 0.0001). In keeping with these findings there was a 
trend towards a lower TLco in those within the moderate 
IPF group (mild 63% predicted ± 9.5), range 50–83% pre-
dicted vs moderate 57% predicted ± 6.2, range 50–65% 
predicted, p = 0.055). No significant difference in the 
6MWT distance measured between mild and moderate 
groups was observed.
Patients with moderate disease had numerically lower 
total K-BILD, chest symptom and psychological domain 
scores compared to those with mild disease, although 
values were not statistically different (total K-BILD 
mild disease 67 (± 10.3) vs moderate disease 60 (± 6.6), 
p = 0.058). There were no significant differences in VAS 
scores of cough, breathlessness or fatigue between mild 
and moderate IPF groups or IPF-PROM measurements.
Whilst baseline CPET values were all within ‘normal’ 
published ranges [20, 28], peak minute ventilation (% 
predicted) was significantly higher for those with moder-
ate IPF compared to those with mild disease (mild 71.0% 
(± 13.9) vs moderate 82.9% (± 12.4, p = 0.045) (Table 1).
Of the baseline CPET parameters measured,  VO2 peak/
kg at anaerobic threshold positively correlated with 
total scores (r = 0.42, p = 0.03), breathlessness/activity 
(r = 0.47, p = 0.014) and chest domains (r = 0.44, p = 0.02) 
of the K-BILD questionnaire (Pearson’s correlation). Sim-
ilarly, total IPF PROM scores and wellbeing domains sig-
nificantly correlated with  VO2 peak (r =  − 0.43, p = 0.02 
and r =  − 0.44, p = 0.02), with a trend towards statisti-
cal significance for total IPF-PROM and  VO2 peak/kg 
at anaerobic threshold (p = 0.06). VE/VCO2 at anaero-
bic threshold also correlated with total K-BILD score 
(r = 0.39; p = 0.001) at baseline, although there were no 
significant correlations with the individual domains of 
the questionnaire or IPF-PROM.
Total K-BILD scores (r = 0.44, p = 0.03) and total IPF-
PROM scores (r =  − 0.43, p = 0.03) both significantly cor-
related with 6MWT distance, but not with baseline FVC 
% predicted (Total K-BILD, p = 0.14; Total IPF-PROM 
p = 0.50), TLco % predicted (Total K-BILD p = 0.16; Total 
IPF-PROM p = 0.32), baseline  or minimum  SpO2 (Total 
K-BILD p = 0.25 and p = 0.32, respectively, Total IPF 
PROM p = 0.53 and p = 0.55, respectively). There were no 
significant correlations between baseline CPET param-
eters and VAS scores (p > 0.05).
Measurements at 1 year follow up
Total IPF cohort
At one year of follow up, the mean reduction in FVC 
and TLco % predicted for the whole IPF cohort (n = 27) 
was − 3.6% (± 7.1, p = 0.02) and − 3.2% (± 7.5, p = 0.04) 
respectively (Additional File 1: Table  1). Whilst sta-
tistically significant, values were below those deemed 
clinically significant [29, 30]. There was no significant 
reduction in 6MWT distance achieved (mean reduc-
tion 4.8  m ± 34.7, p = 0.50; mean reduction in 6MWT 
distance as % theoretical distance 0.2% (± 7.9, p = 0.92). 
There was a statistically significant reduction in the 
breathlessness and activity domain scores of the K-BILD 
questionnaire from baseline to 1  year, suggesting worse 
health status (− 4.8 ± 10.2, p = 0.02), although this did 
not reach the published MCID for responsiveness for this 
domain [27]. There were no statistically significant dif-
ferences in the VAS scores for cough, breathlessness and 
fatigue or in the IPF-PROM from baseline to one year 
(p > 0.05).
Follow up of mild IPF group with repeat CPET
Thirteen patients from the mild IPF group returned for 
repeat CPET at 1 year; the coronavirus COVID-19 pan-
demic prohibited the return of the remaining six patients 
at the one year follow-up time point as planned. All but 
one patient achieved anaerobic threshold.
Upon repeat CPET testing there were statistically sig-
nificant declines in the  VO2 peak (21.6  ml/kg/min ± 2.9 
vs 19.1 ± 2.8; p = 0.017),  VO2 peak at AT (14.2  ml/
kg/min ± 3.2 vs 11.8 ± 1.6, p = 0.044) VE peak (75.3 
L/min ± 20.9 vs 66.1 ± 21.6; p = 0.007), peak work 
(106.9  W ± 26.3 vs 90.8 ± 25.9; p = 0.022) heart rate 
response (142.3 bpm ± 24.0 vs 133 ± 22.3; p = 0.040) and 
increased breathing reserve (BRmax) (21.8 L/min (12.4–
34.2) vs 33.8 (20.2–55.7); p = 0.0002), compared to base-
line values (Table 2).
There was a statistically significant reduction in 
FVC% predicted at 12  months, although the mean 
absolute decline was < 10% (baseline FVC 98.8% pre-
dicted ± 8.5 vs follow up FVC 93.4% predicted ± 10.3, 
p = 0.01). In these same patients, statistically significant 
reductions in breathlessness/activity (− 7.2 ±  − 10.8; 
p = 0.033) and chest (− 9.6 ±  − 15.0; p = 0.040) domain 
scores of the K-BILD questionnaire were observed, with 
a trend towards statistical significance for reduction in 
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Table 1 Baseline characteristics of IPF participants
Characteristic Overall n = 27 Mild n = 19 Moderate n = 8 p value
Age (years) (mean, SD) 75 (± 6.0) 75 (± 6.6) 74 (± 4.3) 0.440
Gender (male n, %) 22, 82% 14, 74% 8, 100% 0.280
Smoking history (n, %)
 Current 0, 0% 0, 0% 0, 0% 0.552
 Never 10, 37% 9, 47% 1, 12.5%
 Ex-smoker 17, 63% 10, 53% 7, 87.5%
BMI (kg/m2) (mean, SD) 28.5 (± 4.5) 28.9 (± 5.0) 27.7 (± 2.9) 0.585
MRC (n) 0.964
 0–1 4 3 1
 2 16 11 5
 3 7 5 2
 4–5 0 0 0
Antifibrotics (n,%) 9, 33% 5, 26% 4, 50% 0.375
Co-morbidities n/s
 Gastro-oesophageal reflux 11 6 5
 Hypertension 10 7 3
 Coronary artery disease 10 4 6
 Diabetes 3 1 2
Lung function parameters (mean, SD)
FVC (L) 2.96 (± 0.72) 3.11 (± 0.78) 2.61 (± 0.46) 0.050
FVC (% predicted) 91 (± 16.0) 99 (± 10.0) 70 (± 5.1)  < 0.0001
FEV1/FVC ratio 78 (± 7.9) 76 (± 7.8) 82 (± 7.2) 0.080
TLco % predicted 61 (± 9.0) 63 (± 9.5) 57 (± 6.2) 0.055
6MWT (mean, SD) n = 25 n = 18 n = 7
Distance achieved (m) 350 (± 63.3) 349 (± 66.6) 354 (± 58.6) 0.827
% theoretical distance (m) 78 (± 16.3) 78 (± 16.5) 76 (± 17.0) 0.821
CPET (mean, SD) n = 27 n = 19 n = 8
VO2 peak/kg (ml/kg/min)* 20.9 (± 3.9) 20.6 (± 4.2) 21.7 (± 3.1) 0.489
VO2/kg at AT (ml/kg/min) 13.6 (± 3.5) 13.8 (± 3.6) 13.0 (± 3.2) 0.585
VE peak (L/min) 69.9 (± 21.1) 69.0 (± 21.7) 72.1 (± 20.9) 0.731
VE peak (% predicted) 74.5 (± 14.4) 71.0 (± 13.9) 82.9 (± 12.4) 0.045
VE/VCO2 at AT 28.2 (± 3.1) 28.7 (± 3.3) 27.2 (± 2.4) 0.201
Minimum  O2 saturation during CPET(%) 91 (± 4.7) 91 (± 5.4) 92 (± 2.8) 0.723
Peak work rate (W) 104.8 (± 26.4) 103.6 (± 29.4) 107.6 (± 18.7) 0.673
Peak work (% predicted) 44 (± 8.6) 44 (± 9.5) 43 (± 6.1) 0.565
HR (bpm) 141 (± 21.8) 141 (± 21.2) 139 (± 24.5) 0.793
HR (% predicted) 97 (± 15.1) 98 (± 15.0) 95 (± 16.2) 0.711
BR max (L/min); median (IQR) 26.5 (18.4–32.5) 28.8 (18.8–33.3) 20.4 (12–24.9), n = 7 0.083
K-BILD questionnaire (mean, SD) n = 27 n = 19 n = 8
 Total 65 (± 9.7) 67 (± 10.3) 60 (± 6.6) 0.058
 Psychological domain 69 (± 17.8) 72 (± 17.8) 61 (± 15.7) 0.128
 Breathlessness and activity domain 56 (± 12.6) 57 (± 13.6) 52 (± 9.4) 0.267
 Chest symptoms domain 78 (± 17.7) 81 (± 18.2) 71 (± 14.6) 0.133
IPF-PROM questionnaire (mean, SD) n = 27 n = 19 n = 8
 Total 20 (± 4.3) 20 (± 4.6) 21 (± 3.5) 0.337
 Physical breathlessness 5 (± 1.5) 5 (± 1.4) 5 (± 1.5) 0.264
 Psychological breathlessness 5 (± 1.3) 5 (± 1.2) 6 (± 1.5) 0.121
 Well-being 5 (± 2.0) 5 (± 2.2) 5 (± 1.3) 0.662
 Energy 5 (± 1.5) 5 (± 1.7) 5 (± 0.8) 0.565
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the total B-ILD score (− 5.6 ±  − 10.4; p = 0.077) at fol-
low up. Notably, the mean unit change of total K-BILD 
and breathlessness/activity domain scores exceeded the 
minimally clinically important difference previously 
reported (5 and 7 unit change respectively) [27], with 
5/13 patients achieving the MCID for total K-BILD 
score and 8/13 for the breathlessness/activity domains 
(Table 3).
There were no statistically significant differences in 
the VAS scores for cough, breathlessness or fatigue VAS 
score from baseline to one year (p > 0.05). There was 
statistically significant worsening in the psychological 
experience of breathlessness as reported by the IPF-
PROM (0.8 ± 1.2, p = 0.044), although the clinical sig-
nificance of this small statistical change is not clear.
Reductions in K-BILD scores observed at 12 months 
were correlated with baseline CPET measurements. 
Lower baseline  VO2 peak/kg at anaerobic threshold 
correlated with greater declines in total K-BILD scores 
(r =  − 0.62, 0.024) and psychological domains of the 
K-BILD at follow up (r =  − 0.63, p = 0.022). No other 
baseline CPET parameters significantly correlated with 
change in K-BILD score in this small cohort, including 
peak work rate. Furthermore, there was no significant 
correlation with the baseline FVC% predicted (p = 0.70) 
All data shown as mean with standard deviation(SD) unless otherwise stated. All visual analogue scores presented as median with interquartile range (IQR). 
*Referenced  VO2 peak/kg for a 75 year old man would be 26.5 ml/kg/min (based on the linear regression equation male =  − 0.42 × age(years) + 58 (Schneider, Lung 
2013 [28]). years years; SD standard deviation; n number; % percentage; FVC forced vital capacity; L litres; FEV1 forced expiratory volume in one second, TLco transfer 
factor; m metres, HR heart rate; MRC medical research council dyspnoea score; VAS visual analogue score; cm centimetres; bpm beats per minute; W Work; O2 oxygen; L 
litres; 6MWT 6 min walk test; BMI body mass index; CPET cardiopulmonary exercise test; K-BILD King’s Brief interstitial lung disease questionnaire; IPF-PROM idiopathic 
pulmonary fibrosis patient reported outcome measure. Unpaired t-test with Welch’s correction was used to compare parametric data of mild and moderate groups, 
whilst Mann Whitney u was used for non-parametric data. Fisher’s exact test was used to compare categorical data. A p < 0.05 was considered statistically significant
Table 1 (continued)
Characteristic Overall n = 27 Mild n = 19 Moderate n = 8 p value
VAS Cough (cm) (median, (IQR)) 1.7 (0.8–2.8) 1.5 (0.2–2.6) 2.3 (1.4–3.0) 0.135
Bristol VAS breathlessness (cm) 1.9 (0.8–3.3) 1.8 (0.8–3.4) 2.4 (1.1–4.7) 0.630
Bristol VAS fatigue (cm) 3.7 (1.1–5.1) 3.7 (1.1–5.1) 3.8 (1.4–6.3) 0.457
Table 2 Baseline and 1 year follow up data for patients within mild group (those with matched tests)
VO2 peak peak oxygen consumption/kg; AT anaerobic threshold; VE minute ventilation; VCO2 carbon dioxide output; VCO2 ventilatory equivalent for carbon dioxide; 
VE/VCO2 BR max breathing reserve; W work; bpm beats per minute; % percentage; IQR interquartile range; n number; 6MWT 6 min walk test; FVC Forced Vital Capacity; 
TLco transfer factor; m metres; % percentage; CPET cardiopulmonary exercise testing. All values are shown as mean ± standard deviation, unless otherwise stated. 
Paired t-test was used for parametric data, whilst Wilcoxon matched pairs signed rank test was used for non-parametric data. A p < 0.05 was considered statistically 
significant
CPET parameters Baseline (n = 13) Follow up (n = 13) p value
VO2 peak (ml/kg/min) 21.6 ± 2.9 19.1 ± 2.8 0.017
VO2 peak at AT (ml/kg/min) 14.2 ± 3.2 11.8 ± 1.6, n = 12 0.044
VE peak (L/min) 75.3 ± 20.9 66.1 ± 21.6 0.007
VE peak % pred 75.5 ± 13.2 65.9 ± 12.2 0.007
VE/VCO2 at AT 29.7 ± 3.1 31 ± 4.6, n = 12 0.353
Minimum  O2 saturation during CPET (%) 91.5 ± 5.5 87.9 ± 6.6, n = 12 0.182
Peak Work (W) 106.9 ± 26.3 90.8 ± 25.9 0.022
Peak Work (% predicted) 44.3 ± 6.9 37.7 ± 8.5 0.002
HR (bpm) 142.3 ± 24.0 133 ± 22.3 0.040
HR (% predicted) 98.7 ± 16.9 91.8 ± 16.8 0.022
BR max (L/min)(median, (IQR)) 21.8 (12.4–34.2) 33.8 (20.2–55.7) 0.0002
6MWT
 Distance achieved (m) 346.9 ± 73.8 340.8 ± 72.4 0.563
 % theoretical distance (m) 76.4 ± 18.3 76.0 ± 16.8 0.872
Lung function
 FVC % predicted 98.8 ± 8.5 93.4 ± 10.3 0.010
 TLco % predicted 62.3 ± 9.4 59.3 ± 11.8 0.161
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or TLco% predicted (p = 0.62) and change in K-BILD 
score (Pearson’s correlation).
Discussion
CPET is considered the gold standard for evaluating exer-
tional dyspnoea and exercise intolerance in patients with 
cardiorespiratory conditions [31], yet currently lacks a 
defined role in the management of ILD [31, 32]. A recent 
systematic review by our group highlighted the insuf-
ficient available evidence to support the use of CPET in 
disease prognostication in ILD, emphasising that hetero-
geneity in terms of the ILD populations studied and the 
retrospective nature of the majority of published studies 
limited the conclusions that could be drawn [33]. Fur-
thermore, the minimally clinically important differences 
for CPET parameters in ILD have not been established.
Our study has shown that CPET can be undertaken 
in both mild and moderate populations of IPF patients, 
without any significant adverse events, although study 
attrition was high and complicated by COVID-19 
restrictions, such that only 64% patients completing the 
protocol.
Our prospective data suggests that baseline CPET  VO2 
peak is associated with clinically-meaningful patient-
perceived reduction in health status at 1 year, in spite of 
comparatively stable lung function parameters (< 10% 
decline in FVC and < 15% decline in TLco).  VO2 peak 
is an integrated measure of respiratory, cardiovascular 
and neuromuscular function [20]. In a progressive dis-
ease such as IPF, the finding of reduced exercise perfor-
mance at one year was not a surprising one. However, 
results suggest that this reduction was not as a conse-
quence of ventilatory limitation. There was no change 
in the CPET ventilatory mode and the development of 
cardiac + / − pulmonary vascular dysfunction was not 
apparent. One possible explanation might be that patients 
became more deconditioned with reduced activity levels 
in response to their perceived worsening of breathless-
ness. El Nagger et  al. [34] have previously shown that 
 VO2 peak correlated with health status of IPF patients at 
baseline as determined by the St Georges questionnaire 
but longitudinal changes in CPET parameters and associ-
ated health status were not explored. In our cohort,  VO2 
peak during exercise correlated with patient reported 
outcome measures at baseline, it significantly declined at 
12 months and also correlated with the change in patient 
reported health status at 12 months.
Existing literature conflicts as to whether  VO2 peak 
might predict disease outcomes in IPF; peak  VO2 thresh-
olds ranging from < 8.3 to < 14.2  ml/kg/min [13, 14, 35] 
have been reported to predict mortality in IPF, whilst 
others studies have failed to identify any significant asso-
ciation [36–38]. Ongoing follow up of our prospective 
cohort will be used to further study the use of baseline 
CPET parameters to predict longer-term outcomes in 
these patients.
It is recognised that this study has limitations. Firstly, 
and perhaps most importantly, the study was con-
ducted on a relatively small and homogenous sample of 
patients. This limits the overall generalisability of results, 
particularly in terms of feasibility of CPET across IPF 
phenotypes; for example those with exercise induced pul-
monary hypertension versus those with relatively normal 
pulmonary vascular response to exercise, and the risk of 
Type II error may be relatively high.
The vast majority of patients had mild IPF (72%) with 
a median MRC score of 2; again limiting the generalis-
ability of results. Whilst it would have been preferable 
to have a broader range of symptomatic patients, exer-
cise in patients with high MRC scores would be very 
restricted leading to early completion of tests before 
the limit of pulmonary and cardiovascular systems 
had been reached [39] and thus negatively influencing 
the results. A further limitation of the study was that 
almost a quarter of patients enrolled in the study devel-
oped exclusions to CPET or were lost to follow up; a 
factor that will be helpful to inform power calcula-
tions for future studies involving CPET as an outcome 
measure. It was decided by the study committee in the 
planning of the protocol that due to the uncertainty of 
the ability and the safety of those with reduced lung 
Table 3 Change in K-BILD, IPF-PROM and Visual analogue scores 
of mild IPF patients with repeat CPET at 1 year follow up
Results shown as mean change in questionnaire score with standard deviations 
(SD), unless otherwise stated. Paired t-test used for parametric data and 
Wilcoxon matched pairs signed rank test for non-parametric data. K-BILD King’s 
Brief interstitial lung disease questionnaire; IPF-PROM Idiopathic pulmonary 
fibrosis-patient reported outcome measure; VAS visual analogue scale; cm 
centimetres. p value < 0.05 considered statistically significant
Unit change 
(mean, SD) n = 13
p value
K-BILD questionnaire
 Total  − 5.6 (± 10.4) 0.077
 Psychological domain  − 5.2 (± 18.8) 0.304
 Breathlessness and activity domain  − 7.2 (± 10.8) 0.033
 Chest symptoms domain  − 9.6 (± 15.0) 0.040
IPF-PROM
 Total 1.5 (± 0.9) 0.109
 Physical breathlessness 0.5 (± 1.4) 0.189
 Psychological breathlessness 0.8 (± 1.2) 0.044
 Well-being  − 0.2 (± 1.2) 0.656
 Energy 0.4 (± 1.4) 0.337
VAS Cough (cm) median  − 1.6 0.391
Bristol VAS breathlessness (cm) median 0.0 0.716
Bristol VAS fatigue (cm) median  − 0.1 0.956
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function to perform a maximal exercise test, those in 
the ‘moderate’ disease group would undertake only a 
baseline CPET test. In retrospect, it would have been 
more valuable to undertake repeat CPET on all enrolled 
participants. With the experience gained from this 
study, this is something that could be explored in the 
future.
It is recognised by the authors that the selection of 
reference value equations can have a significant impact 
on the interpretation of CPET results [20], for exam-
ple, the 220-age equation may underestimate HRmax 
in older adults [20]. The authors have used reference 
equations to contextualise the results where appropri-
ate, recognising that many existing reference equations 
are not fully representative of the male dominant and 
elderly population characteristic of IPF populations.
Finally, the COVID-19 pandemic adversely affected 
the ability to perform follow-up CPET testing, particu-
larly in this highly vulnerable group of individuals; con-
sequently the resulting sample size was small.
Conclusion
In conclusion, our study provides the initial data to 
support the feasibility of CPET in at least mild-mod-
erate populations of IPF and the ability of repeated 
CPET to assess the change in health status over time. 
This may be clinically applied in the future to assess the 
response to pharmacological or non-pharmacological 
interventions from the patient’s perspective. Future 
work should concentrate on examining the relation-
ship between CPET parameters, lung function and CT-
derived measures of disease, establishing the MCID for 
longitudinal change in CPET in ILD.
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